Distribution and Characteristics of Escherichia coli Clonal Group A1 by Johnson, James R. et al.
Distribution and
Characteristics of
Escherichia coli
Clonal Group A
1
James R. Johnson,*† Andrew C. Murray,*†
Michael A. Kuskowski,*† Sören Schubert,‡
Marie-Francoise Prère,§ Bertrand Picard,¶ 
Raul Colodner,# Raul Raz,#** and the 
Trans-Global Initiative for Antimicrobial
Resistance Analysis (TIARA) Investigators2
Among 1,102 recent Escherichia coli clinical isolates,
clonal group A was identified in 17 of 20 (U.S. and non-
U.S.) geographic locales, mainly among U.S. isolates (9%
vs. 3%; p < 0.001) and those resistant to trimethoprim-sul-
famethoxazole (10% vs. 1.7%; p < 0.001). The extensive
antimicrobial resistance and virulence profiles of clonal
group A may underlie its recent widespread emergence.
The Study
The recently recognized Escherichia coli clonal group
A (CGA) accounts for up to 50% of trimethoprim-sul-
famethoxazole (TMP-SMZ)–resistant E. coli from U.S.
women with acute uncomplicated cystitis and pyelonephri-
tis (1–3). Available data show CGA to exhibit a stereotyp-
ical virulence factor (VF) profile and a conserved
multidrug antimicrobial resistance phenotype, i.e., to
ampicillin, chloramphenicol, streptomycin, sulfonamides,
tetracycline, and trimethoprim (ACSSuTTp), which is
conjugally transferable on a large plasmid (1,2). Together
with CGA’s unusual O antigens (O11, O17, O73, and
O77), these findings suggested that CGA represents a
newly emerged virulent clonal group (1,2). CGA’s homo-
geneity across geographic locales, and the indistinguish-
able pulsed-field gel electrophoresis (PFGE) profiles of
clustered CGA isolates within 1 community (1), suggested
recent and possibly ongoing dissemination, a novel para-
digm for extraintestinal pathogenic E. coli (ExPEC) (4). 
To date, CGA has been studied only within the United
States, predominantly among women with uncomplicated
urinary tract infections (UTI). Its occurrence in some
locales has been questioned (5), and its antimicrobial sus-
ceptibility profile has been assessed for only 12 drugs
(1,2,6). Accordingly, we sought to more fully define the
global distribution, host range, virulence characteristics,
and resistance phenotypes of CGA.
Twenty clinical microbiology laboratories (10 U.S., 10
non-U.S.) each provided approximately 25 consecutive
TMP-SMZ–resistant and TMP-SMZ–susceptible E. coli
isolates, except for 2 laboratories that provided resistant
isolates only (Table 1). Isolates were distributed by speci-
men type (urine/other) and source (inpatient/outpatient).
Antimicrobial drug–resistant and –susceptible isolates
were collected approximately concurrently during 2001
from each site, except London (1999) (7) and Columbus
(1999 and 2002). When available, data regarding specimen
type and host gender, age, and inpatient/outpatient status
were provided. 
Phylogenetic group (A, B1, B2, or D) was defined by
triplex polymerase chain reaction (PCR) (8). Group D iso-
lates were defined as CGA if by random amplified poly-
morphic DNA (RAPD) analysis they resembled CGA
controls with primers 1254 and 1290, or with one of these
plus >2 of primers 1247, 1281, or 1283 (2). PFGE analy-
sis used XbaI (1). 
CGA isolates and (2:1) geographically matched con-
trols selected randomly based on the local TMP-SMZ
resistance prevalence were tested for 35 ExPEC-associat-
ed virulence markers and 13 papA alleles by PCR (2).
Such typing predicts experimental in vivo virulence (9).
Isolates were defined as ExPEC if positive for > 2 of papA
and/or papC, sfa/foc, afa/dra, iutA, and kpsM (10). The
aggregate virulence score was the number of different vir-
ulence markers detected in an isolate, adjusted for multiple
detection of certain operons. 
O typing was carried out by the E. coli Reference
Center (University Park, PA). O antigens O1, O2, O4, O6,
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 1, January 2005 141
1Presented in part at the American Society for Microbiology 103rd
General Meeting, May 18-22, 2003, Washington, D.C.
2The TIARA investigators include the following: Sacared Bodison
(University of Maryland, College Park, MD), Franklin R. Cockerill,
III (Mayo Clinic and Mayo Medical School, Rochester, MN), Clovis
Arns da Cunha (Curitiba-PR, Brazil), Peter Echeverria and Sriluck
Simasathien (Armed Forces Research Institute of Medical
Sciences and Phramonkutkho Army Hospital, Bangkok, Thailand),
Wim Gaastra (University of Utrecht, Utrecht, The Netherlands),
Lucinda M.C. Hall (St Bartholomew's and the Royal London
School of Medicine and Dentistry, London, UK), Marina Klein
(McGill University Health Centre, Montreal, Quebec, Canada),
Hank A. Lockman (Battelle Memorial Institute, Columbus, OH),
Imad Omer and Jane R. Schwebke (University of Alabama,
Birmingham, AL), Guillem Prats (Hospital Vall d'Hebron,
Barcelona, Spain), Robert M. Rakita (Virginia Mason Medical
Center, Seattle, WA), Susan Rossman (Texas Childrens Hospital,
Houston, TX), Ronald Schifman (Southern Arizona VA Medical
Center, Tucson, AZ), Ronald Smith (Billings Clinic and Providence
Medical Center, Billings, MT), and Patricia L. Winokur (VA Medical
Center and University of Iowa, Iowa City, IA). 
*VA Medical Center, Minneapolis, Minnesota, USA; †University of
Minnesota, Minneapolis, Minnesota, USA; ‡Max von Pettenkofer-
Institut für Hygiene und Medizinische Mikrobiologie, München,
Germany; §Centre Hospitalier Universitaire Purpan, Toulouse,
France; ¶Hôpital Morvan, Brest, France; #HaEmek Medical Center,
Afula, Israel; and **Technion School of Medicine, Afula, IsraelO7, O16, O18, O25, and O75 were considered UTI-asso-
ciated (O-UTI) (10).
Susceptibility testing of the isolates to 30 drugs was car-
ried out by broth microdilution (11) or disk diffusion (nitro-
furantoin) (11), by using E. coli ATCC 25299 for reference
and National Committee for Clinical Laboratory Standards
(NCCLS)–specified interpretative criteria (12), except for
kanamycin, spectinomycin, and streptomycin (resistant at
MICs of >25 mg/L, >128 mg/L, and >8 mg/L, respective-
ly). The aggregate resistance score was the number of dif-
ferent agents to which an isolate exhibited resistance. 
Statistical analysis used a Fisher exact or a chi-square
test for comparisons of proportions and the Mann-Whitney
U test for comparisons of scores. Multiple variables were
assessed as predictors of selected outcomes by multivari-
ate logistic regression or multiple linear regression. 
The 1,102 clinical E. coli isolates were divided evenly
by U.S. and non-U.S. origin and TMP-SMZ resistance sta-
tus (Table 2). Overall, phylogenetic group B2 predominated
(44%), followed by group D (27%). Group D was signifi-
cantly more prevalent among U.S. than non-U.S. isolates
(34% vs. 21%: p < 0.001). TMP-SMZ–resistant isolates
exhibited significant shifts from group B2 toward groups A,
D, or both. The nearly 2-fold greater prevalence of group D
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isolates, the “B2 > D” pattern of susceptible isolates.
By RAPD analysis, 23% of group D isolates (6%
overall) represented CGA (Table 2). CGA was strongly
associated with TMP-SMZ resistance (10% of resistant
isolates, 1.7% of susceptible: p < 0.001) and a U.S. origin
(9% vs. 3%: p < 0.001). CGA accounted for 15% of U.S.
TMP-SMZ–resistant isolates and 5% of those from abroad
(p < 0.001), but for a similarly low proportion of U.S. (2%)
and non-U.S. (1.5%) susceptible isolates. According to
multivariate logistic regression analysis, after accounting
for TMP-SMZ resistance and U.S. origin, none of the other
source variables (specimen type and host gender, age, and
inpatient/outpatient status) was significantly associated
with CGA status or appreciably altered the association of
TMP-SMZ resistance or U.S. origin with CGA status (not
shown).
CGA occurred in all but 3 locales (1–10 isolates per
locale), accounting for up to 29% of local resistant isolates
(median, 9.5%) (Table 1). CGA was highly prevalent
(20%–25%) among resistant isolates from the 3 pediatric
centers (Columbus, Houston, and Toulouse) and the veter-
ans’hospital (Tucson). Toulouse exhibited the highest non-
U.S. CGA prevalence, whereas nearby Brest lacked CGA
(Table 1). CGA accounted for 29% of the ostensibly non-
clonal (5) TMP-SMZ–resistant isolates from Chicago.
Consistent with this, XbaI PFGE profiles of 6 Chicago and
2 reference CGA isolates were highly similar (Figure 1).
CGA isolates differed significantly from controls,
according to almost all characteristics analyzed; they were
significantly enriched with the O11, O17, and O77 anti-
gens, certain VFs (F16 papA allele, papAHCEFG, papG
allele II, iha, iutA, kpsM II, traT, and ompT), and ExPEC
status, but lacked other traits (Figure 2). Aggregate viru-
lence scores were similar for CGA and controls (medians,
8.0) but were less diverse for CGA (range 5–9, vs. 1–13).
By multivariate logistic regression, both CGAstatus and
phylogenetic group B2 were significant independent pre-
dictors of ExPEC status, with CGAexhibiting an odds ratio
(OR) of 21.9 (95% confidence interval [CI], 6.1–78.2; p <
0.001), and group B2 an OR of 2.4 (CI, 1.7–3.4; p < 0.001).
Additionally, by multiple linear regression, CGA status
(standardized regression coefficient [β] = 0.57; p < 0.001)
and group B2 status (β = 0.596; p < 0.001) predicted VF
score better than did O-UTI (β = 0.32; p = 0.002).
Antimicrobial resistance phenotypes were compared
between CGA isolates and a subset of the controls, which
had been selected to provide an unbiased distribution of
TMP-SMZ resistance (Figure 2). CGA exhibited a higher
prevalence of resistance to 10 individual drugs, any drug,
and ACSSuTTp, whereas controls exhibited a low but
measurable prevalence of resistance to 7 drugs to which all
CGA isolates were susceptible. Accordingly, resistance
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Figure 1. XbaI pulsed-field gel electrophoresis profiles of
Escherichia coli clonal group A(CGA) isolates and E. coli O157:H7.
Lane numbers are shown below the gel image. Six CGA isolates
from Chicago, IL ("A" series identifiers; lanes 1, 3, 4, 5, 7, and 8)
exhibit similar profiles to reference CGA isolates SEQ102 (from
California; lane 2) and UMN26 (from Minnesota; lane 6) (1). E. coli
O157:H7 isolate G5244 (lane 9) exhibits a distinctive profile.scores were significantly higher for CGA than controls
(median 8.0 [range 1–11] vs. 5.5 [range 0–15]; p = 0.001).
Among TMP-SMZ–resistant isolates, TMP-SMZ MICs
ranged from 32/608 mg/L to >520/9,880 mg/L; 61% of
resistant isolates had MICs >520/9,880 mg/L. CGA
accounted for 67% of this highly resistant population (p =
0.01 vs. controls).
The U.S. and non-U.S. CGA isolates exhibited only 2
statistically significant differences for VF profiles, O anti-
gens, and resistance phenotypes, with iroN (p = 0.03) and
absence of ompT (p = 0.008) associated with non-U.S.
isolates.
Conclusions
We found that the recently described E. coli CGA is
globally but heterogeneously distributed and more preva-
lent within the United States than abroad. Clonal group A
affects diverse host populations (including inpatients, out-
patients, adults, children, men, and women), infects uri-
nary tract and nonurinary tract sites, is strongly associated
with TMP-SMZ resistance (particularly high-level resist-
ance), and exhibits a robust virulence profile suggesting
enhanced extraintestinal virulence. This combination of
resistance and virulence may account for CGA’s recent
emergence as a broadly disseminated “epidemic clone”
(1–3,6,13,14).
The greater overall prevalence of CGA within the
United States suggests a U.S. origin for CGA. However, it
also could reflect more rapid clonal expansion within the
United States due to enhanced dissemination or more
favorable conditions for outgrowth, including possibly less
competition from other potential occupants of the same
niche(s). The variable prevalence of CGA among even
closely situated locales, both within the United States and
abroad, might reflect true geographic heterogeneity, versus
locale-specific differences in patient populations, selection
criteria, and collection intervals. Studies that compare
well-defined, homogeneous, concurrent populations from
different locales are needed.
The new evidence of CGA as a prominent TMP-
SMZ–resistant pathogen among children and veterans
extends the known host range of CGA, consistent with a
recent report of CGA as a community-wide TMP-SMZ-
resistant pathogen in Denver, Colorado (6). This finding
illustrates CGA’s pathogenic versatility. 
That 29% of the TMP-SMZ–resistant isolates from
Chicago, Illinois, proved to be CGA and resembled refer-
ence CGA isolates by PFGE, despite a previous PFGE-
based assessment of nonclonality (5), illustrates the
limitations of conventional PFGE analysis as a screen for
CGA. We have developed a CGA-specific PCR assay,
based on a single nucleotide polymorphism within fumC,
to provide improved screening for CGA (15).
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Figure 2. Virulence traits (top) and antimicrobial resistance pheno-
types (bottom) of Escherichia coli clonal group A (CGA) isolates
versus non-CGA controls. Percentage of isolates positive for each
virulence trait (top) or resistance phenotype (bottom) is shown by
black bars to left of midline (for CGA) or grey bars to right of mid-
line (for controls). No isolates were positive for bmaE (M fimbriae),
or resistant to amikacin, aztreonam, cefepime, ceftazidime,
ertapenem, imipenem-cilistatin, nitrofurantoin, piperacillin-tazobac-
tam, or ticarcillin-clavulanate. p value symbols at right of each
chart, from Fisher exact or  χ2 test, indicate significant differences
between CGA and non-CGA. *, p <0.05; **, p <0.01; ***, p <0.001.CGA’s robust, highly homogeneous consensus VF pro-
file (F16 papA allele, papG allele II, iutA, kpsM II, traT,
and ompT) suggests considerable extraintestinal virulence
potential, an inference supported by experimental data
indicating that CGA is able to compete successfully with
classic group B2-derived pathogens in a mouse UTI model
(J.R. Johnson, unpub. data). Determination of which VFs
of CGA contribute most to pathogenicity may identify
future targets for preventive interventions.
In our study, antimicrobial resistance was more exten-
sive and, with TMP-SMZ, more potent for CGA than con-
trols. These factors may be contributing to CGA’s global
emergence. Conceivably, high-level TMP-SMZ resistance
could allow CGA to out-compete even other TMP-
SMZ–resistant strains. CGA’s resistance involved primari-
ly older agents, whereas fluoroquinolone and
cephalosporin resistance was confined to controls.
However, the emergence of fluoroquinolone resistance
within the closely related O15:K52:H1 clonal group (2,13)
suggests that this potential exists also for CGA.
The study’s strengths include large population, broad
geographic sampling, matching of CGA and control iso-
lates, and extensive range of traits analyzed. Limitations
include the heterogeneous inclusion criteria, gaps in glob-
al surveillance, possible type I errors from multiple com-
parisons, and limited sampling per locale.
In summary, we found CGA to be a globally dissemi-
nated, multidrug-resistant clonal group of pathogenic E.
coli with a broad range of human hosts. Although more
prevalent within the United States than abroad, CGA
exhibits characteristic O antigens, resistance markers, and
virulence traits wherever encountered. Further study is
needed of the origins, virulence mechanisms, geographic
distribution, clinical associations, and modes of dissemina-
tion of CGA.
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